Read by QxMD icon Read

Diabetes & Metabolism

Simon Lebech Cichosz, Finn Redke, Ole K Hejlesen
AIM: - Our study investigated the relationship between both spontaneous and iatrogenic hypoglycaemia and mortality. METHODS: - A total of 200,859 patients from the eICU Collaborative Research Database were grouped by whether they had registered episodes of hypoglycaemia or not. Patients with hypoglycaemia were then further divided into subgroups according to type of hypoglycaemia-whether spontaneous or iatrogenic. Spontaneous hypoglycaemia during an ICU stay was defined as one or more registered blood glucose measurements < 70 mg/dL (3...
February 15, 2019: Diabetes & Metabolism
Mourad Benalia, Marianne Zeller, Basile Mouhat, Charles Guenancia, Valentin Yameogo, Camille Greco, Hermann Yao, Maud Maza, Bruno Vergès, Yves Cottin
BACKGROUND: - In patients with type 2 diabetes (T2D), glycaemic variability (GV), another component of glycaemic abnormalities, is a novel potentially aggravating factor for coronary artery disease (CAD). OBJECTIVES: - The aim of our study was to identify interactions between GV and severity of CAD in diabetes patients admitted for acute myocardial infarction (AMI). METHODS: - All patients with T2D admitted to our university hospital for AMI from March 2015 to February 2017 who received intravenous (IV) insulin therapy and underwent coronary angiography were included...
February 11, 2019: Diabetes & Metabolism
Alessandro Mantovani, Chiara Zusi, Elena Sani, Antonio Colecchia, Giuseppe Lippi, Gianluigi Zaza, Luca Valenti, Christopher D Byrne, Claudio Maffeis, Enzo Bonora, Giovanni Targher
AIM: - Evidence is emerging that PNPLA3 rs738409 polymorphism (the major genetic variant associated with susceptibility to non-alcoholic fatty liver disease [NAFLD]) is associated with chronic kidney disease (CKD) in non-diabetic individuals. Currently, little is known about this association in type 2 diabetic (T2DM) patients with and without NAFLD. METHODS: - We studied 101 Caucasian post-menopausal women with T2DM, consecutively attending our diabetes outpatient service during a 3-month period...
February 11, 2019: Diabetes & Metabolism
Liang Cheng, Yun-Yun Li, Hu Wen, Feng Bai, Hai-Rong Hao, Wei-Nan Yu, Xiao-Ming Mao
AIM: To evaluate the association between sodium-glucose cotransporter-2 (SGLT2) inhibitors and risk of bone fractures in patients with type 2 diabetes mellitus (T2DM). METHODS: A systematic literature search conducted of PubMed, Embase, the Cochrane Library and Web of Science from inception up to 31 August 2018 identified all eligible randomized controlled trials (RCTs). The following data were extracted from each study: first author; year of publication; sample size; patient characteristics; study design; intervention drug; control drug; follow-up durations; and incident bone-fracture events...
February 6, 2019: Diabetes & Metabolism
Sylvie Picard, Dimitar Vasilevski, Guy Fagherazzi
No abstract text is available yet for this article.
January 31, 2019: Diabetes & Metabolism
André J Scheen
Patients with type 2 diabetes mellitus (T2DM) are exposed to non-alcoholic fatty liver disease (NAFLD), a comorbidity associated with cardiovascular disease and chronic kidney disease, and which may progress to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Sodium-glucose cotransporter type-2 (SGLT2) inhibitors are glucose-lowering agents that improve glucose control while promoting weight loss and lowering serum uric acid levels. These agents may exert cardiovascular and renal protection in T2DM patients with established cardiovascular disease...
January 29, 2019: Diabetes & Metabolism
L Monnier, C Colette, J-L Schlienger, B Bauduceau, D R Owens
Recognizing the role of dysglycaemia, 'ambient' hyperglycaemia, 'metabolic memory' and glycaemic variability as risk factors for macrovascular diseases is mandatory for effective diabetes management. Chronic hyperglycaemia, also referred to as 'ambient hyperglycaemia', was only fully acknowledged as a risk factor for adverse cardiovascular events when the beneficial effects of intensive glucose-lowering strategies were consolidated in the extended follow-up (> 10 years) of patients included in the United Kingdom Prospective Diabetes Study (UKPDS) and Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study...
January 24, 2019: Diabetes & Metabolism
B Guerci, B Charbonnel, P Gourdy, S Hadjadj, H Hanaire, M Marre, B Vergès
Despite the availability of a large number of therapeutic options throughout the world, rates of optimal glycaemic control in adult patients with type 2 diabetes mellitus remain low. Delays in treatment intensification to insulin and low adherence to insulin regimes, which are well-documented contributors to poor glycaemic control, are in many cases driven by fear of hypoglycaemic events, weight gain and injections. Over the last 10 years, injectable glucagon-like peptide-1 receptor agonists (GLP1-RAs) have emerged as alternatives to basal insulin for treatment intensification in patients inadequately controlled with oral antidiabetic drugs...
January 21, 2019: Diabetes & Metabolism
Rui Wei, Tianpei Hong
No abstract text is available yet for this article.
January 17, 2019: Diabetes & Metabolism
Jose Luis Martin-Rodriguez, Jorge Gonzalez-Cantero, Alvaro Gonzalez-Cantero, Luis Martí-Bonmatí, Ángel Alberich-Bayarri, Trinidad Gonzalez-Cejudo, Jorge Luis Gonzalez-Calvin
AIM: The association of non-alcoholic fatty liver disease (NAFLD) with insulin resistance (IR) is well established, yet little is known of their possible relationship with intrahepatic iron and serum tumour necrosis factor (TNF)-α concentrations in adults without diabetes. Thus, this study looked at the relationship of intrahepatic iron and serum TNF-α with intrahepatic triglycerides and IR in non-diabetic adults. METHODS: In this cross-sectional study of 104 healthy non-diabetic Caucasians, a quantitative magnetic resonance (MR) imaging T2 gradient-echo technique was used to measure hepatic iron, with 1H-MR spectroscopy used to measure hepatic triglycerides...
January 17, 2019: Diabetes & Metabolism
Alexandre Lugat, Hélène Caillon, Lucy Chaillous, Bertrand Cariou, Delphine Drui
No abstract text is available yet for this article.
January 17, 2019: Diabetes & Metabolism
Tingting Wang, Wanlin Zhang, Mingzhi Zhang, Yonghong Zhang, Shaoyan Zhang
AIM: The study examined the association between resting heart rate and risk of type 2 diabetes (T2D) and cardiovascular events in an Inner Mongolian population. METHODS: Based on a cross-sectional survey carried out in 2003, 2530 participants were reinvestigated between 2013 and 2014. All participants were classified into four groups (quartiles) according to heart rate. Primary outcomes were hypertension, T2D, major macrovascular events and all-cause deaths. Logistic regression models were used to estimate odds ratios (ORs), and shape-restricted cubic spline regressions were conducted to investigate the associations between resting heart rate and study outcomes...
January 11, 2019: Diabetes & Metabolism
Ja Young Jeon, Soo-Kyung Kim, Kyung-Soo Kim, Sun Ok Song, Jae-Seung Yun, Bo-Yeon Kim, Chul-Hee Kim, Seok O Park, Seongbin Hong, Hea Seo, Ji A Seo, Jung Hyun Noh, Dae Jung Kim
AIM: - This study investigated the clinical characteristics of diabetic ketoacidosis (DKA) and compared the DKA characteristics between patients treated with and without SGLT2 inhibitors. METHODS: - Data were collected from patients aged ≥ 18 years admitted for DKA at nine centres in Korea between September 2014 and April 2017. The electronic medical records of these subjects were retrospectively reviewed. Based on their history of medications taken before admission, subjects were classified as either users or non-users of SGLT2 inhibitors and their clinical characteristics of DKA were compared...
January 9, 2019: Diabetes & Metabolism
Vanita R Aroda, Andrew Ahmann, Bertrand Cariou, Francis Chow, Melanie J Davies, Esteban Jódar, Roopa Mehta, Vincent Woo, Ildiko Lingvay
In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor management reduces the likelihood of late-stage diabetic complications. Guidelines recommend treatment goals targeting HbA1c, body weight, blood pressure, and low-density lipoprotein cholesterol. Development of new treatments for type 2 diabetes requires an understanding of their mechanism and efficacy, as well as their relative effects compared to other treatment choices, plus demonstration of cardiovascular safety. Subcutaneous semaglutide is a glucagon-like peptide-1 receptor agonist currently approved in several countries for once-weekly treatment of type 2 diabetes...
January 4, 2019: Diabetes & Metabolism
Nick Sr Lan, B Yeap Bu, Damon A Bell, Gerald F Watts, P Gerry Fegan
No abstract text is available yet for this article.
January 1, 2019: Diabetes & Metabolism
E Cosson, E Vicaut, D Sandre-Banon, F Gary, I Pharisien, J-J Portal, I Banu, L Bianchi, C Cussac-Pillegand, R Dina, S Chiheb, P Valensi, L Carbillon
AIMS: In addition to screening for hyperglycaemia during pregnancy after 24 weeks of gestation (WG), the current guidelines also suggest screening in early pregnancy and referring women with early gestational diabetes mellitus (eGDM) or overt diabetes (OD) for immediate care. Our aim was to evaluate this strategy. METHODS: This study evaluated, at our hospital (2012-2016), whether the incidence of a predefined composite outcome (preeclampsia, large-for-gestational-age infant, shoulder dystocia) and secondary outcomes was different when women were screened only after 22WG ('late screening only') or before 22WG and treated for eGDM or OD if present, with repeat screening after 22WG if absent ('early ± late screening')...
November 28, 2018: Diabetes & Metabolism
D R Owens, T S Bailey, C Fanelli, J-F Yale, G B Bolli
AIM: Second-generation basal insulin analogues (e.g. insulin degludec, insulin glargine 300 U/mL), were designed to further extend the duration of insulin action and reduce within-day and day-to-day variability, and consequently hypoglycaemia risk, versus earlier long-acting basal insulins. This review examines the pharmacokinetic/pharmacodynamic characteristics of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL), and their influence on clinical outcomes. METHODS: Available pharmacokinetic/pharmacodynamic publications comparing insulin degludec and insulin glargine were reviewed...
November 26, 2018: Diabetes & Metabolism
J-C Chauvet-Gélinier, A-L Mosca-Boidron, C Lemogne, S Ragot, N Forestier, D Callegarin, C Allard, A Rebaï, B Bouillet, E Ponavoy, I Simoneau, J-M Petit, G Bondolfi, P Callier, B Trojak, B Bonin, B Vergès
AIM: Type A personality has been associated with increased survival in people with type 1 diabetes (T1D). Systemic low-grade inflammation may play a critical role, as suggested in recent reports, although the links between the inflammatory circulating transcriptome and Type A remain unknown. This prompted our exploration of the potential associations between Type A personality and c-Fos gene expression, a candidate gene closely linked to inflammatory processes, in T1D. METHODS: Type A personality was assessed by Bortner questionnaire in patients with T1D, and two subscales - 'speed' and 'competitiveness' - were used to measure these specific dimensions of Type A...
November 23, 2018: Diabetes & Metabolism
F Bonnet, A J Scheen
Chronic low-grade inflammation is a recognized key feature associated with type 2 diabetes mellitus (T2DM) and its complications. In prospective randomized trials, sodium-glucose cotransporter type 2 (SGLT2) inhibitors have demonstrated benefits related to several cardiovascular and renal risk factors, including HbA1c , blood pressure, body weight, renal hyperfiltration, and improvement of cardiorenal outcomes. SGLT2 inhibitors may improve adipose tissue function and induce decreases in serum leptin, TNF-α and IL-6 while increasing adiponectin...
December 2018: Diabetes & Metabolism
F Maillard, S Rousset, B Pereira, Y Boirie, M Duclos, N Boisseau
No abstract text is available yet for this article.
December 2018: Diabetes & Metabolism
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"